1. Home
  2. PRAX vs IGIC Comparison

PRAX vs IGIC Comparison

Compare PRAX & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • IGIC
  • Stock Information
  • Founded
  • PRAX 2015
  • IGIC 2001
  • Country
  • PRAX United States
  • IGIC Jordan
  • Employees
  • PRAX N/A
  • IGIC N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • IGIC Property-Casualty Insurers
  • Sector
  • PRAX Health Care
  • IGIC Finance
  • Exchange
  • PRAX Nasdaq
  • IGIC Nasdaq
  • Market Cap
  • PRAX 952.1M
  • IGIC 1.0B
  • IPO Year
  • PRAX 2020
  • IGIC N/A
  • Fundamental
  • Price
  • PRAX $52.00
  • IGIC $23.21
  • Analyst Decision
  • PRAX Strong Buy
  • IGIC Buy
  • Analyst Count
  • PRAX 10
  • IGIC 2
  • Target Price
  • PRAX $93.30
  • IGIC $31.50
  • AVG Volume (30 Days)
  • PRAX 435.3K
  • IGIC 86.8K
  • Earning Date
  • PRAX 11-05-2025
  • IGIC 11-04-2025
  • Dividend Yield
  • PRAX N/A
  • IGIC 0.86%
  • EPS Growth
  • PRAX N/A
  • IGIC 11.00
  • EPS
  • PRAX N/A
  • IGIC 2.79
  • Revenue
  • PRAX $7,765,000.00
  • IGIC $535,109,000.00
  • Revenue This Year
  • PRAX N/A
  • IGIC $6.05
  • Revenue Next Year
  • PRAX $20.00
  • IGIC $7.01
  • P/E Ratio
  • PRAX N/A
  • IGIC $8.38
  • Revenue Growth
  • PRAX 338.45
  • IGIC 9.99
  • 52 Week Low
  • PRAX $26.70
  • IGIC $18.45
  • 52 Week High
  • PRAX $91.83
  • IGIC $27.76
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 56.68
  • IGIC 41.32
  • Support Level
  • PRAX $46.99
  • IGIC $22.91
  • Resistance Level
  • PRAX $55.86
  • IGIC $23.83
  • Average True Range (ATR)
  • PRAX 3.62
  • IGIC 0.57
  • MACD
  • PRAX 0.56
  • IGIC -0.05
  • Stochastic Oscillator
  • PRAX 74.41
  • IGIC 20.75

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About IGIC International General Insurance Holdings Ltd.

International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.

Share on Social Networks: